Noventure is delighted to announce the launch of Tasectan® in Russia by its partner company Jadran, under the umbrella brand Adiarin®

Adiarin®  is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia.

Tasectan® in Europe is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Novinthetical Pharma SA). In Russia,  Adiarin® has been granted local marketing authorization as class II medical device. 

Read more: http://noventure.com/magazine